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Objective: Total hip replacement (THR) and total knee replacement (TKR) (arthroplasty) surgery for end-
stage osteoarthritis (OA) are ideal candidates for optimization through an algorithmic care pathway.
Using a comparative effectiveness study design, we compared the effectiveness of a new clinical pathway
(NCP) featuring central intake clinics, dedicated inpatient resources, care guidelines and efﬁciency
benchmarks vs the standard of care (SOC) for THR or TKR.
Methods: We compared patients undergoing primary THR and TKR who received surgery in NCP vs SOC
in a randomised controlled trial within the trial timeframe. 1,570 patients (1,066 SOC and 504 NCP
patients) that underwent surgery within the study timeframe from urban and rural practice settings
were included. The primary endpoint was improvement in Western Ontario and McMaster University
Osteoarthritis Index (WOMAC) overall score over 12 months post-surgery. Secondary endpoints were
improvements in the Physical Function (PF) and Bodily Pain (BP) domains of the Short Form 36 (SF-36).
Results: NCP patients had signiﬁcantly greater improvements from baseline WOMAC scores compared to
SOC patients after adjusting for covariates (treatment effect¼ 2.56; 95% conﬁdence interval (CI) [1.10e
4.01]). SF-36 BP scores were signiﬁcantly improved for both hip and knee patients in the NCP (treatment
effect¼ 3.01, 95% CI [0.70e5.32]), but SF-36 PF scores were not. Effects of the NCP were more pronounced
in knee patients.
Conclusion: While effect sizes were small compared with major effects of the surgery itself, an evidence-
informed clinical pathway can improve health related quality of life (HRQoL) of hip and knee arthroplasty
patients with degenerative joint disorder in routine clinical practice for up to 12 months post-operatively.
Clinicaltrials.gov identiﬁer: NCT00277186.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: C. Frank, Alberta Bone and
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s Research Society International. PIntroduction
Controlling the escalating costs of medical interventions
without compromising the quality of care has created the need for
innovative system reorganization, ideally validated by comparative
effectiveness trials, to help inform sustainable solutions1e3.
Comparative effectiveness compares treatment options where
outcomes are evaluated in routine clinical practice1e4. Total hip
replacement (THR) and total knee replacement (TKR) (arthroplasty)
surgery for end-stage osteoarthritis (OA) are ideal candidates forublished by Elsevier Ltd. All rights reserved.
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growing5,6 and delivery is not yet optimised. While others have
evaluated improved “clinical pathways” for arthroplasty sur-
gery7e15, to date only one small randomised controlled study has
performed a comparison of a care pathway approach to a less
algorithmic care plan that considers patient outcomes and health
related quality of life (HRQoL) beyond the acute care timeframe9.
To address this gap, a partnership of surgeons, afﬁliated
healthcare providers and decision support researchers designed
and implemented a new evidence-informed clinical pathway for
patients requiring THR or TKR and compared the clinical outcomes
of that approach to the standard of care (SOC) using a randomised
controlled comparative effectiveness study design16. The new
clinical pathway (NCP) differed from the SOC by including stand-
alone central intake clinics with case managers, dedicated inpa-
tient and operating room resources, evidence based guidelines for
care, and benchmarks for efﬁciencies. The SOC is the routine clinical
practice, which generally varied by surgeon and clinic. This paper
reports on the 3- and 12-month effectiveness outcomes of NCP vs
SOC patients that received surgery within the study timeframe.
Methods
Design overview
We conducted a large scale pragmatic randomised controlled
trial of patients with a degenerative joint disorder who received
THR or TKR within the study timeframe, following an evidence-
informed accelerated clinical pathway vs the SOC.
The procedures followed were in accordance with the ethical
standards of the responsible committee on human experimenta-
tion (institutional and national) and with the Helsinki Declaration
of 1975, as revised in 2000. The study received ethical approval
from the University of Calgary Ethics Review Board (Study ID
17951), the University of Alberta Ethics Review Board (Study ID
5660) and the College of Physicians and Surgeons of Alberta Ethics
Review Board (Study ID REC-1376). The trial was registered with
clinicaltrials.gov (NCT00277186). All patients were required to
provide written consent to participate in the study.
Setting and participants
Twenty high-volume orthopaedic surgeons participated in three
health regions representing both urban and rural practice settings
(Calgary, Edmonton and Red Deer) that perform roughly 80% of
THRs and TKRs in the province of Alberta. Surgeon’s ofﬁces
provided their patient lists of potential study participants to the
Alberta Bone and Joint Health Institute (ABJHI) (a third-party
responsible for the study). Patients were enrolled by mail or in
person at patient information sessions held at the central intake
clinics. Patients were excluded if they: (1) had surgery date booked
within 3 months; (2) were not residents of Alberta; (3) were not
referred for a hip or knee condition; (4) were candidates for hip
resurfacing, partial knee replacement or revision surgery; (5) were
under 18 years of age; or (6) had a condition that would contrain-
dicate their ability to fully participate. All included patients were
undergoing primary joint replacement for degenerative joint
disease. Patients were consented, enrolled and randomised
between April 1, 2005 and May 4, 2006. All patients who received
surgery before June 30, 2006, when the trial was stopped, were
included and all were followed for 12 months post-operatively.
Using published standard deviations17 of 17.2, 20.3 and 23.3 for
changes in the Western Ontario and McMaster University Osteo-
arthritis Index (WOMAC) (100 point scale) Short Form 36 (SF-36)
Bodily Pain (SF-36 BP) and SF-36 Physical Function (SF-36 PF)respectively, baseline scores of at least 35, and an alpha level of
0.05, a minimum sample size of 300 per group was determined to
provide approximately 80% power to detect clinically meaningful
differences of 15% in the WOMAC scores and secondary SF-36
outcomes. However, the provincial government provided funding
for up to 1,200 patient hip and knee replacement surgeries in the
NCP within the study timeframe. As a consequence, we evaluated
all randomized patients receiving surgery within the study time-
frame, thereby exceeding the minimum number of patients
required by the sample size calculations.
Randomisation and interventions
The NCP is an accelerated comprehensive care plan from patient
referral through 12 months post-surgery with follow-up at 2-year
intervals16,18. Unique features of the NCP include: (1) stand-alone
central intake clinics with case managers; (2) dedicated inpatient
and operating room resources; (3) guidelines for care including
surgical preparation, medical optimization, patient and family
education, mobilization on the day of surgery; and (4) benchmarks
for efﬁciencies such as duration of inpatient stay, acute care & sub-
acute care discharge criteria, and treatment guidelines (e.g., venous
thrombosis prophylaxis). Details regarding the development of the
NCP have been published previously16 and its efﬁciencies evaluated
independently by government19.
Computer generated randomisation tables in permuted blocks
of four were used to randomly allocate patients into the interven-
tion (NCP) or control (SOC). Randomisation was stratiﬁed by
surgeon, joint type (hip or knee) and patient referral category
(waiting for surgery, waiting for consult or new referral). Upon
receipt of completed consent forms and baseline patient ques-
tionnaires, a research coordinator randomised patients and
assigned them a unique study identiﬁcation number.
Orthopaedic surgeons and anaesthetists provided care to
patients in both study groups to ensure that physician character-
istics were comparable while all other clinical and hospital staff
only provided care within either the NCP or SOC group.
Outcomes and follow-up
Effectiveness treatment effects were measured objectively using
validated disease speciﬁc and generic patient-reported HRQoL
instruments. The primary outcome was improvement in the
WOMAC version 3.0 overall score over 12 months post-surgery20.
Secondary outcome measures were improvements in two clinically
relevant domains of the Medical Outcomes SF-36 version 2: SF-36
PF and SF-36 BP21 over 12 months post-surgery.
Baseline patient questionnaires were collected for all patients
who consented. A research assistant mailed 3-month and
12-month post-surgery questionnaires to patients, and reminded
them by telephone to complete their questionnaires. Patients were
contacted within 24 h of receipt of a completed questionnaire to
resolve missing or invalid data. Surgical dates were obtained from
administrative data and clinic staff.
Patient-completed questionnaires were also used to collect
demographics; employment and working status; smoking (current
or quitting within 12 months of consent); body mass index (BMI;
kg/m2); chronic disease score (CDS) derived from patient self-
reported medication prescriptions, but excluding medications
used to treat degenerative joint disorder; concurrent hypertension
or diabetes; and medications used for hip or knee pain22. Ques-
tionnaires at 3 and 12 months post-surgery collected additional
data pertaining to adverse events, acceptability of treatment, and
satisfaction. American Society of Anaesthesiologists (ASA) Physical
Status Classiﬁcation System score (ASA score) was obtained from
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the group allocation.
A total of 4,985 patients were invited to participate, of which
3,434 (69%) consented and were randomised (Fig. 1). Due to
accelerated access to surgery prescribed in the NCP, a total of 1,066
of 1,722 patients received surgery and had 12-month follow-up in
the NCP [451 TKR, 615 THR] whereas 504 of 1,712 patients received
surgery and comparable 12-month follow-up in the SOC [226 TKR,
278 THR] within the study timeframe. Of the 1,551 patients that did
not consent, 9% violated the exclusion criteria, 83% refused for
personal reasons and 8% declined for other reasons.
Patient questionnaire response rates were 90.0% and 78.8% at
3 months, and 86.2% and 80.2% at 12 months for the NCP and SOC,
respectively.
Safety review and adverse events
A safety committee used the Canadian Patient Safety Institute’s
deﬁnition of an adverse event as “an event which results inA
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Fig. 1. Patient recruitment, studunintended harm to the patient, and is related to the care and/or
services provided to the patient rather than the patient’s under-
lying medical condition”24. Possible adverse events were identiﬁed
from multiple data sources and assessed by a blinded physician
Safety Review Committee.
Adverse events that occurred within 30 days of surgery and
were either identiﬁed to be clinically important (regardless of
frequency), or those that occurred at a rate of 0.5% or more in either
study group, were reported. For comparison, estimates of adverse
events for THR and TKR patients were obtained from 2004 Alberta
Health and Wellness administrative data.
Statistical analysis
Statistical analysis was conducted on SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA) and STATA 10, special edition (STATA
Corporation, College Station, Texas, USA). We used a conservative
approach to compare outcomes by analyzing the data based oned to participate
85
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y allocation and follow-up.
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ciple. We summarised the distributions of continuous variables
with means and standard deviations and categorical/binary vari-
ables as percentages. For continuous and categorical/binary vari-
ables, t-tests and Chi-square tests, respectively, were used to
compare baseline characteristics. The primary and secondary
outcomes were transformed to scales with a score of 0 indicating
maximal disability and 100 indicating no disability17,25.
We analysed primary and secondary outcome treatment effects
using a linear mixed model with a random intercept to assess
treatment effects over 12 months post-surgery to account for the
correlation between repeated measurements in these longitudinal
data. Linear mixed models do not require balance in the number of
outcomes at each point in time and are considered superior to last-
observation-carried forward methods for the analysis of data in
randomized control trials26e28. We included the following baseline
variables in the models: age, gender, race, urban residence,
smoking status, referral category, surgical joint, BMI, ASA score and
CDS. We evaluated the effects of time (3 vs 12 months) and
a treatment-by-time interaction. We assessed WOMAC post
surgery ceiling effects, deﬁned as a score of 90e100 points, using
Chi-square tests.
Two subgroup analyses were performed: the interaction of
intervention group by joint (TKR and THR) and intervention group
by the patient’s referral category. Only statistically signiﬁcant
interactions were included in the ﬁnal model. For all linear models,
we also tested assumptions of linearity, homoscedasticity and
normality.Table I
Baseline characteristics for SOC control and NCP intervention patients who did and did n
Measure SOC
Control
(n¼ 1712)
Non-surgical*
(n¼ 1208)
Demographic information
Age (mean SD) (Years) 65.8 12.0
Female % 55.1
Race (white) % 91.7
Urban % 84.0
Employed % 35.9
Retired % 41.0
Smoker % 13.6
Joint % Hip 36.4
Knee 63.6
Referral categoryz (%) One & two-waiting
for consult or surgery
29.1
Three-new referrals 70.9
Clinical characteristics
BMI (mean SD) (kg/m2) 30.0 6.0
ASA score 3%z NA*
CDS (mean SD) 3545.4 3841.8
Hypertension % 47.3
Diabetes % 12.4
Pain medicationsx (mean SD) 1.3 1.4
Quality of life scores
WOMAC (mean SD) Pain 49.8 18.9
Stiffness 44.3 20.9
Function 48.8 19.8
Overall 48.5 18.7
SF-36 (mean SD) BP 31.4 17.8
PF 32.4 22.9
ASA score not obtained for patients who did not receive surgery within the study timefr
* Non-surgical: did not receive surgery within the study timeframe.
y Surgical: received surgery within the study timeframe.
z Referral category: 1¼ those already seen, consented and waiting for surgery; 2¼ th
them for assessment of their hip or knee symptoms.
x Pain medications¼ drug strength times drug quantity divided by the deﬁned daily dMissing data
The observed patterns of missing data were not amenable to
a last-observation-carried forward method because there were
patients with observations at 12 months that did not have obser-
vations at 3 months. Instead, we used linear mixed models, which
use all available data and provide a ﬂexible approach for modelling
outcomes in the presence of missing data as described above.
Results
There were no statistically signiﬁcant differences in baseline
scores or demographics except NCP patients were more likely to be
from an urban setting and a higher percentage were new referrals
(Table I). Of the 3,434 patients in the study, 1,570 were surgical
patients. 98.1% of the patients had non-inﬂammatory arthritis
(including OA, OA primary and secondary to trauma or avascular
necrosis). The remaining 1.9% patients had a primary diagnosis of
either Rheumatoid Arthritis, Gout, congenital hip dysplasia or other
diagnosis. A total of 232 surgical patients chose to switch from their
assigned intervention or control study group e 125 patients from
the NCP to SOC, and 107 patients from SOC to NCP.
WOMAC-overall scores improved 37.5 and 34.5 points from
baseline to 12 months for the NCP and SOC respectively (Table II).
Improvements from baseline to 12 months were also observed for
the SF-36 PF (31.2 for NCP; 29.0 for SOC) and SF-36 BP scores (36.8
for NCP; 33.7 for SOC).
After adjusting for the baseline WOMAC and other covariates,
the treatment effect of the NCP on the WOMAC-overall score overot receive surgery within the study timeframe (n¼ 3,434)
NCP
Intervention
(n¼ 1722)
P-value
Surgicaly
(n¼ 504)
Non-surgical*
(n¼ 656)
Surgicaly
(n¼ 1066)
Surgical SOC vs
surgical NCP
69.0 10.4 64.3 12.3 69.0 11.1 0.998
59.9 52.8 60.4 0.869
94.4 91.0 94.1 0.779
80.2 84.3 84.8 0.021
29.5 37.9 29.5 0.970
45.4 40.2 45.9 0.857
13.7 14.6 15.2 0.431
44.8 34.6 42.4 0.354
55.2 65.4 57.6
72.0 29.0 50.3 <0.001
28.0 71.0 49.7
29.4 5.4 30.1 6.1 29.5 5.6 0.682
24.2 NA* 21.6 0.257
3185.0 2403.9 3698.3 4066.0 3132.5 2270.6 0.675
52.2 41.0 51.1 0.696
11.7 13.7 12.9 0.521
1.7 1.8 1.3 1.9 1.6 1.6 0.681
45.9 17.5 52.8 20.2 44.9 17.6 0.260
40.0 19.4 46.7 20.8 39.4 40.0 0.565
45.0 18.1 51.7 20.4 43.3 17.1 0.080
44.8 17.0 51.4 19.5 43.3 16.3 0.100
28.2 16.7 34.5 18.7 27.4 16.6 0.354
27.1 19.8 36.2 24.5 26.1 20.2 0.338
ame.
ose previously referred and waiting for a consult; and 3¼ new patients referred to
ose.
Table III
Treatment effect of the NCP intervention compared to the SOC control for patients
receiving surgery within the study timeframe (n¼ 1,570)
Outcome Intervention
treatment effect
95% CI P-value
Primary outcome
WOMAC-overall Adjusted* 2.56 [1.10, 4.01] 0.001
Un-adjusted 2.64 [1.18, 4.10] <0.001
Secondary outcomes
SF-36 PF Adjusted* 1.88 [0.34, 4.09] 0.097
Un-adjusted 2.41 [0.08, 4.74] 0.042
SF-36 BP Adjusted* 3.01 [0.70, 5.32] 0.011
Un-adjusted 3.52 [1.21, 5.84] 0.003
* Intervention effect from mixed linear regression models with random intercept
adjusting for age, gender, smoking status, CDS, ASA score (3 vs >3), BMI, patient’s
residence (urban vs rural), joint type, time (12 months vs 3 months), referral cate-
gory (waiting for consult/surgery or new referrals) and baseline score on outcome
measure (WOMAC-overall or SF-36 PF or SF-36 BP).
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[1.10e4.01]; P¼ 0.001] (Table III). NCP treatment effects were 1.88
(95% CI [0.34e4.09]; P¼ 0.097) for SF-36 PF and 3.01 (95% CI
[0.70e5.32]; P¼ 0.011) for SF-36 BP (Table III). The effect of treat-
ment in the NCP did not depend on waiting time for any of the
outcome measures.
At 3 months post-surgery, a signiﬁcantly larger proportion of
patients in the NCP demonstrated ceiling effects on the WOMAC
compared to the SOC (30.2% vs 19.7%; c2 (1)¼ 15.47, P< 0.001). At
12 months post-surgery, a larger proportion of patients had ach-
ieved a ceiling score, and perhaps as a result, the difference
between groups was no longer signiﬁcant (39.9% vs 35.0%; c2 (1)¼
2.97, P¼ 0.090).
Subgroup analysis (adjusted results not shown)
The primary analysis did not distinguish between hip and knee
patients. We conducted a subgroup analysis that examined
whether there were differences between hip patients and knee
patients in the effects of treatment. To perform this subgroup
analysis, we used models that included surgical joint by treatment
group interaction terms.
For the WOMAC-overall, the effect of treatment in the NCP did
notdependon the joint (hip orknee).However, the improvement for
hip patients frombaseline over 12 monthswas greater than for knee
patients (adjusted difference¼ 4.19; 95% CI [2.81e5.57]; P< 0.001).
For the SF-36 PF, the effect of treatment in the NCP was greater
for knees than for hips (adjusted difference¼ 5.17; 95% CI
[0.84e9.49], P¼ 0.019]). There was no effect of the NCP on SF-36 PF
outcomes for hip surgery, but for knee surgery there was greater
improvement in the NCP (adjusted difference¼ 4.27; 95% CI
[1.33e7.20]; P¼ 0.004).
Similarly, we performed a subgroup analysis to examine
whether there were differences between patients in different
referral categories.The effect of the NCP on outcome scores did not
depend on referral category.
Adverse events (within 30 days of surgery)
All adverse events within 30 days of surgery occurred at a rate of
less than 1.1% with either intervention (Table IV). For NCP patients,Table II
Un-adjustedmean of outcomes at baseline, 3 months and 12 months post-surgery for SOC
Outcome Joint Baseline
SOC
Control
(n¼ 504)
NCP
Inter
(n¼
WOMAC-overall (mean SD) Combined 44.8 17.0 43.3
Change from baseline
Hip 42.0 16.3 39.9
Change from baseline
Knee 47.0 17.2 45.8
Change from baseline
SF-36 PF (mean SD) Combined 27.1 19.8 26.1
Change from baseline
Hip 24.9 19.5 24.8
Change from baseline
Knee 28.9 20.0 27.1
Change from baseline
SF-36 BP (mean SD) Combined 28.2 16.7 27.4
Change from baseline
Hip 26.6 15.6 24.8
Change from baseline
Knee 29.6 17.5 29.3
Change from baseline
Combined: hip and knee.the most frequently reported adverse event was hip dislocation
which, at 1.1%, (5/451) was the only adverse event noted to be
higher than historical rates from provincial administrative hospital
discharge data. NCP rates were similar to historical rates while,
several SOC rates were unusually low (e.g., no hip dislocations and
no cardiac events).Discussion
This randomised controlled trial compared the clinical effective-
ness of a NCP vs the SOC in routine practice for surgical patients
treated in three health regions that performabout 80% of all THRs and
TKRs in Alberta. Our results demonstrated that the NCP signiﬁcantly
improvedHRQoL outcomes for both THR and TKR patients over those
in the SOC, as measured by small but greater improvements in
disease-speciﬁc WOMAC-overall and generic SF-36 BP scores over
12 months post-surgery. The effects of theNCPweremore obvious for
TKR. From a clinical perspective, this is likely because of the focus on
early mobilization in the NCP that may reduce stiffness and scarring,
which is a bigger problemwith knees.
To put these results in a broader clinical context, our results also
reconﬁrmed that THRs and TKRs are highly effective at 3 monthscontrol and NCP intervention patients receiving surgery within the study timeframe
3 months 12 months
vention
1066)
SOC
Control
(n¼ 397)
NCP
Intervention
(n¼ 959)
SOC
Control
(n¼ 404)
NCP
Intervention
(n¼ 919)
 16.3 76.1 14.5 79.2 14.3 80.1 15.8 81.4 15.8
30.9 18.3 36.0 18.4 34.5 19.2 37.5 19.2
 16.5 79.3 13.8 81.1 14.6 82.3 15.0 83.2 15.6
36.2 18.1 41.2 18.5 39.2 17.9 42.4 19.2
 15.7 73.5 14.6 77.8 13.9 78.2 16.3 80.1 15.8
26.4 17.2 32.2 17.4 30.4 19.4 33.8 18.3
 20.2 50.8 25.2 53.5 24.4 56.2 26.5 57.3 26.3
23.3 23.4 27.7 23.7 29.0 24.7 31.2 25.7
 22.2 55.4 25.1 52.6 26.6 59.1 27.9 58.4 27.7
29.2 23.6 28.5 25.3 33.6 24.7 33.9 27.5
 18.6 47.0 24.8 54.2 22.6 53.8 25.0 56.5 25.3
18.4 22.2 27.0 22.4 25.1 24.0 29.1 24.1
 16.6 58.0 23.2 61.9 23.6 62.3 24.5 64.6 26.1
28.8 24.0 34.5 25.0 33.7 25.0 36.8 26.6
 16.4 63.8 22.7 66.3 24.2 66.1 23.4 66.4 26.8
35.1 24.0 41.5 25.3 38.2 24.6 41.3 27.4
 16.6 53.2 22.6 58.7 22.6 59.2 25.1 63.3 25.5
23.6 22.8 29.4 23.6 29.7 24.7 33.5 25.5
Table IV
Inpatient mortality and adverse events* within 30 days of surgery for SOC control and NCP intervention patients receiving surgery within the study timeframe
Adverse event type* SOC
Control
(N¼ 504)
NCP Intervention
(N¼ 1,066)
Rate for Alberta 1 year before
hip and knee pilot project
(N¼ 4,913)x
Number of
adverse eventsz
Rate per 100 Number of
adverse eventsz
Rate per 100 Rate per 100
Inpatient mortality 0 0 4 0.38 0.45
Joint related
Dislocation (hip)y 0/226 0 5/451 1.10 0.69 (15/2183)
Deep vein thrombosis 2 0.40 1 0.09 2.81
Fracture intra-operative 3 0.60 5 0.47 N/A
Fracture related to site 2 0.40 2 0.19 N/A
Deep infection 3 0.60 5 0.47 N/A
Pulmonary embolism 4 0.79 9 0.84 1.06
Not joint related
Acute myocardial infarction 0 0 8 0.75 0.76
Pneumonia 3 0.60 3 0.28 1.98
Renal failure 1 0.20 3 0.28 N/A
Stroke/cerebrovascular accident 0 0 1 0.09 0.80
Atrial ﬁbrillation 4 0.79 6 0.56 N/A
Narcotic induced respiratory
distress/failure
3 0.60 3 0.28 N/A
N/A: not available.
* Adverse events were reviewed and conﬁrmed by the Safety Review Committee, which was blinded to patient identity, treatment assignment and surgeon.
y There were 226 hip surgeries in the SOC and 451 hip surgeries in the NCP.
z A patient can have more than one adverse event.
x Rate of adverse events from Alberta Health andWellness administrative data [Hospital discharge data (DAD) and Ambulatory data (ACCS)] in 2004 for all patients who had
Primary Hip and Knee Replacement in Alberta. The year 2004 was selected because it was prior to start of the trial.
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primary and secondary un-adjusted mean HRQoL outcome
measures from baseline of greater than 29 points. Although THR
score improvements were higher than for TKRs, both dramatically
alleviated pain, restored function and improved the quality of
life29,30. While there is no well-accepted standard for a minimal
clinically important difference, changes of 15e25 points inWOMAC
scores31e33 and 10e20 points on SF-36 PF have been considered to
be clinically important in the context of surgery and rehabilitation.
In contrast, our study compares two different clinical pathways for
joint replacement and the reported treatment effects are incre-
mental to those of the surgery itself. While the effects of surgery
were thus clearly clinically important, the effects of the NCP were
much more modest, adding improvements of 2e3 points to HRQoL
outcome scores over 12 months, after adjusting for other cova-
riates. While small, nonetheless, NCP effects were statistically
signiﬁcant, even 12 months post-surgery.
Further, it is important tonote that themagnitudeofNCPeffects in
this study was likely underestimated for several reasons. First, the
conservative analysis with 232 total switches from assigned groups
diluted treatment effects from the NCP. When patients who crossed
over between treatment groupswere excluded from the analysis, the
adjusted treatment effect of the NCP intervention increases (from
2.56 to 3.24 for WOMAC-overall, from 1.88 to 2.94 for SF-36 PF and
from 3.01 to 4.16 for SF-36 BP), and is statistically signiﬁcant for all
primary and secondary endpoints (results not shown). Second, there
was a higher proportion NCP patients with post surgery WOMAC
ceiling scores. Third, it was observed that NCP practices were being
adopted in all settings as the trial proceeded, further minimizing
measured differences. Surgeons and anaesthetists were the same in
each group because surgeons could not be totally blinded in this
design. Patient care in theNCPwasdeliveredby trainedstaff different
from those who delivered care in the SOC, and randomisation was
stratiﬁed by surgeon. While this could be considered a potential
study limitation, this only affects outcomes of some variables (e.g.,
operating minutes), not patient-reported outcomes, and also likely
even further underestimates the NCP treatment effect. Since thetreatment group allocation could not be blinded, another potential
study limitation is the risk of bias on the outcomes from patients
knowing the treatment group to which they were randomized. This
would be expected in any comparative effectiveness studywhere the
treatment allocation is not blinded.
In terms of assessing all potential impacts, we note that overall
adverse event rates for both study groups were low and consistent
with published ranges34e40. While the rates of mortality and
myocardial infarction in the NCP were numerically higher than the
SOC, a detailed safety committee review concluded that adverse
events in both study groups were within expected ranges compared
to reported rates in provincial administrative data and the Canadian
Joint Replacement Registry41. The only adverse event rate that
appeared to be higher than reported in administrative data was the
hip dislocation rate of 1.1% in the NCP (vs 0.7% historically) and 0% in
the SOC. While raising a potential concernwith the NCP, numbers of
many adverse eventswere too low tomake any deﬁnitive conclusion.
To the authors’ knowledge, this study is the largest to compare
a NCP to an existing approach for the delivery of THR and TKR, and
the ﬁrst to follow patients beyond the acute care timeframe to
12 months post-surgery. Our sample size of 1,570 randomised
patients who received surgery exceeded power requirements to
compare patient outcomes. Due to the accelerated access to surgery
in the NCP, more NCP received surgery and had 12-month follow-
up within the study timeframe than in the SOC group. Equal
follow-up periods were essential for comparing treatment effects
and the time required for all SOC patients to complete their surgery
and follow-up was beyond the pre-speciﬁed 12-month study
timeframe. To address this potential concern, we tested statistically
for imbalances, and controlled for measured baseline differences in
the analysis. We did not ﬁnd evidence of imbalances between
surgical patients in the NCP and SOC at baseline, except that
patients in the NCP were more likely to be from an urban setting
and a higher percentage were new referrals. We conﬁrmed that the
effect of the NCP on outcomes did not depend on referral category.
Nonetheless, it is possible that some undetected selection bias
could have inﬂuenced outcomes.
Table I
Major areas of change in each stage of the NCP for TKR and THR
Stage NCP
Referral  Standardized referral templates
 Choice to refer to next available surgeon
 Benchmark wait times for ﬁrst orthopaedic
consult
Pre-surgery  Establishment of central intake clinics
 Case manager assigned to each patient
 Patient “buddy system” for all clinical
encounters
 Patient education session
 Increased patient awareness and
accountability via patient contracts for
pre-surgery optimization and deﬁning
expectations post-surgery
 Standardized criteria for health resource
use pre-surgery (e.g., physiotherapy,
homecare assessments)
 Pre-booking for all clinic and medical
visits and procedures
K. Gooch et al. / Osteoarthritis and Cartilage 20 (2012) 1086e10941092We considered a clustered RCT design since a clinical pathway is
a complex intervention, but it was determined that this was not
a suitable and practical design to address our research question.
Our research question focussed on evaluating a care model that
features a centralized intake clinic, and consequently, there would
only be three clusters deﬁned in Alberta42.
The ﬁndings from this comparative effectiveness study support
hip and knee replacements as effective surgical procedures, which
were further improved by an accelerated clinical pathway
approach.While effect sizes weremodest compared with themajor
effects of the surgery itself, an evidence-informed accelerated
clinical pathway can still further improve both disease speciﬁc and
generic HRQoL of both hip and knee arthroplasty patients in
routine clinical practice over 12 months post-operatively.
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Table I (continued )
Stage NCP
Surgery and
inpatient length
of stay (LOS)
 Benchmark wait times for surgery
 Standardized pain, anti-thrombosis,
nausea and anaesthesia protocols
 Benchmark inpatient and sub-acute care LOS
 Estimated inpatient LOS
 Pre-determined discharge criteria
 Dedicated operating room teams
 Dedicated THR and TKR inpatient beds
 Mobilization on day of surgery
Post-surgery  Measurement of patient outcomes
 Standardized criteria for health resource
use post-surgery e.g., physiotherapy,
occupational therapy, homecare
All  Implementation of information templates
to enhance processes and adherence to
the NCP
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